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Abstract
Aim of the study The estimation of the upper reference
limit (URL) for autoantibodies against thyroid peroxidase
(TPOAbs) is a controversial issue, because of an uncer-
tainty associated with the criteria used to correctly define
the reference population. In addition, the URL of TPOAbs
is method-dependent and often arbitrarily established in
current laboratory practice. The aim of this study was to
determine the reference limits of TPOAbs in a male sample
according to the National Academy of Clinical Biochem-
istry (NACB) guidelines, and to compare them with those
obtained in a female group, for five third-generation
commercial-automated immunoassay (IMA) platforms.
Methods 120 healthy males and 120 healthy females with
NACB-required characteristics (younger than 30 years,
TSH between 0.5 and 2.0 mIU/L, normal thyroid ultra-
sound, absence of thyroid disease and absence of other
autoimmune diseases) were studied. Sera were analyzed for
TPOAbs concentration using five IMA methods applied in
automated analyzers: Immulite 2000 XPi (IMM); Maglumi
2000 Plus (MAG); Kryptor Compact Plus (KRY); Phadia
250 (PHA) and Liaison XL (LIA).
Results A statistically significant difference (p\ 0.05)
between medians in male and female groups was observed
for PHA (2.6 and 3.1 IU/mL, respectively) but not for the
other four methods. Scatter plots of TPOAbs values
revealed a wide dispersion with very different coefficients
of variation between the five methods, varying from
48.6 % for KRY in females to 126.3 % for MAG in
females. The URLs differed in males and females
according to the method: 28.7 and 29.0 IU/mL for IMM,
24.6 and 25.4 IU/mL for MAG, 6.4 and 6.9 IU/mL for
KRY, 8.3 and 10.0 IU/mL for PHA and 14.2 and 17.9 IU/
mL for LIA, respectively. Such URLs were lower than
those stated by the manufacturers except for LIA in
females. The difference between URLs ranged from a
minimum of 11.3 % (LIA in males) to a maximum of
66.8 % (PHA in males).
Conclusions Differences in URLs could result from the
different coating preparations of the TPO antigen (purified
native or recombinant) on solid phase, which affect the
proper exposure of the immunodominant epitopes recog-
nized by the polyclonal antibodies present in serum of
patients with autoimmune thyroid disease (AITD). Based
on these findings, we suggest to overcome the proposal of
the NACB guidelines which recommend to involve a single
group of young male subjects, and propose, instead, to
utilize two distinct groups: one of males and one of
females. This new proposal removes the apparent contrast
of an all-male reference group for a disease (such as AITD)
that affects mainly females. However, in spite of the har-
monization among methods provided by the use of an
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international standard preparation, the wide dispersion of
quantitative results still observed in this study suggests the
need for further efforts to better understand the cause of
these discrepancies, focusing on TPO antigen preparations
as the possible source of variability among different assays.
Keywords Autoimmune thyroid disease  Reference
limits  Thyroid peroxidase autoantibodies  Automation 
Immunoassay  Harmonization
Introduction
Autoantibodies against thyroid peroxidase (TPOAbs) are
both diagnostic hallmarks and early indicators of autoim-
mune thyroid disease (AITD), playing an important pre-
dictive role in healthy subjects, in pregnant women and in
high-risk patients [1–3].
In recent years, refinements in autoantigen preparation
and better selection of polyclonal and monoclonal anti-
bodies have led to a new (third) generation of automated
quantitative immunoassays (IMAs) with improved sensi-
tivity and specificity for the measurement of TPOAbs [4,
5]. Despite their recently expanded use in clinical labora-
tories [6–8], it is yet unclear whether these more-sensitive
automated third-generation IMAs have made improve-
ments in terms of diagnostic accuracy and harmonization
compared with previous methods [9, 10]. Hence, further
efforts in defining the threshold values of positivity need to
be made in order to avoid misclassification of patients with
AITD [9].
The estimation of the upper reference limit (URL) for
TPOAbs is a controversial issue, because of an uncertainty
as to the criteria for correctly defining the reference popu-
lation. The currently proposed direct methods are described
in the National Academy of Clinical Biochemistry (NACB)
guidelines, which recommend the use of a reference group
composed of 120 men with the following features: younger
than 30 years, biochemically euthyroid (serum TSH
between 0.5 and 2.0 mIU/L), without goiter as proven by
ultrasound investigation, no personal/family history of
either thyroid disease or of non-thyroid autoimmune dis-
eases [11]. These guidelines are in themselves difficult to
apply or standardize. Furthermore, it is perplexing, in that it
requires a male reference group for diseases (AITD) that
predominantly affect females [12]. Hence, in developing
commercial methods for TPOAbs quantification, manu-
facturers are faced with difficulties in following the NACB
recommendations. Consequently, results obtained by dif-
ferent researchers using different analytical methods show a
wide variation in URLs [8–10, 13, 14]. In addition, the
definition of reference intervals for TPOAbs has limitations
due to the natural history of AITD, because a large number
of individuals may have specific autoantibodies in serum
10–15 years before the onset of these diseases. To over-
come this problem and avoid the risk of enlisting apparently
healthy subjects who may bear TPOAbs, an indirect method
for the definition of reference limits was proposed by some
authors [12, 15]. Using this approach, the URL values were
lower than those obtained by direct methods. Also, they
displayed sex-dependent differences [15]. Nevertheless, the
indirect method also has limitations, being applicable only
to the single method used in the population sample con-
sidered in that particular study.
Taking into account that TPOAbs reference limits are
method dependent and often arbitrarily established in the
current laboratory practice [9, 10, 16], the aim of this study
was to determine the URL of TPOAbs in a male sample
according to the NACB guidelines, and to compare it with
that obtained in a female group, applying and comparing
five third-generation commercial automated IMA
platforms.
Methods
120 males and 120 females with NACB-required charac-
teristics (younger than 30 years, TSH between 0.5 and 2.0
mIU/L; normal thyroid ultrasound; absence of autoimmune
and non-autoimmune thyroid disease and absence of other
autoimmune diseases) were enrolled in the study. They
came from a large health survey called ‘Thyroid takes to
the square,’ carried out in the province of Verona (Italy)
from 2008 to 2013, in which 7970 subjects with no pre-
vious or current thyroid disease symptoms were screened
by clinical history, thyroid function test, and thyroid
ultrasound. All participants gave their informed consent.
The sera of the 120 males and 120 females were ana-
lyzed for TPOAbs concentration using five IMA methods
applied in automated analyzers: Immulite 2000 XPi (IMM)
(Siemens Healthcare Diagnostics, Flanders, NJ, USA);
Maglumi 2000 Plus (MAG) (Shenzen New Industries
Biomedical Engineering-SNIBE, Shenzen, China); Kryptor
Compact Plus (KRY) (BRAHMS Thermo Scientific,
Henningsdorf, Germany); Phadia 250 (PHA) (Phadia AB,
Uppsala, Sweden) and Liaison XL (LIA) (DiaSorin,
Saluggia, Italy).
All assays were performed according to the manufac-
turers’ instructions at four different laboratories in Friuli
Venezia Giulia region (Italy): Pordenone (IMM and
MAG), S. Vito al Tagliamento (KRY), Tolmezzo (PHA),
and Udine (LIA).
The main features of the five methods are shown in
Table 1.
The Immulite 2000 XPi was a continuous random-ac-
cess system designed around a proprietary assay tube that
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allowed for efficient washing of an integral antibody- or
antigen-coated polystyrene beads as solid phase. This assay
used an alkaline phosphatase enzyme label that was
quantified with a sensitive chemiluminescent substrate
(adamantyl-dioxetane phosphate) by creation of an unsta-
ble adamantyl-dioxetane anion. The breakdown of this
unstable anion generated a prolonged glow of light [17].
The TPOAbs test was based on a sequential chemilumi-
nescent IMA (CLIA), which used native purified TPO
antigen coated on the solid phase. As stated by the man-
ufacturer, the intra-assay imprecision was 4.9–6.3 %; the
total imprecision was 6.1–8.1 %; the limit of detection
(LoD) of TPOAbs assay was 5.0 IU/mL and the limit of
quantitation (LoQ) was not declared.
The Maglumi 2000 Plus was a continuous random-ac-
cess IMA system that used N-(aminobutyl)-N-(ethyl)-iso-
luminol (ABEI) as luminescence substrate and magnetic
particles serving both the solid phase and the separator in a
liquid phase, with two different monoclonal antibodies
labeled with either ABEI or fluorescein-5-isothiocyanate
[18]. The TPOAbs test was a sandwich CLIA with native
TPO coated to nanomagnetic microbeads. According to the
manufacturer, the intra-assay imprecision was 6.8–7.3 %;
the between-assay imprecision was 7.4–7.6 %; the LoD of
the method was 0.38 IU/mL and the LoQ was not declared.
The Kryptor Compact Plus was an IMA system, based
on time-resolved amplified cryptate emission technology
(TRACE), which measured the signal emitted from an
immunocomplex with a time delay. The basis of the
TRACE technology was non-radioactive energy transfer
from a donor to an acceptor. The donor was a cage-like
structure with an europium ion in the center (cryptate); the
acceptor was part of a chemically modified, light-collecting
algal protein (XL 665). The proximity of the donor to the
acceptor intensified the fluorescent signal of the cryptate
and extended the life-span of the acceptor signal, permit-
ting the measurement of temporarily delayed fluorescence
[19]. The TPOAbs test was a competitive fluorescence
IMA (FIA) that used enzymatically active native purified
TPO. As stated by the manufacturer, the intra-assay
imprecision was 2.1–7.6 %; the between-assay imprecision
was 5.8–16.0 %; the LoD was 1.8 IU/mL and the LoQ was
9.0 IU/mL.
The Phadia (previously known as UniCAP, then
ImmunoCAP) 250 was a fully integrated analyzer designed
for the testing of allergy and autoimmune diseases. The
reagents for the autoimmune diagnostics were based on the
well-established EliA, normal ELISA-type-coated wells,
that used b-D-galactosidase-labeled antibodies as tracer
and 4-methyl-umbelliferyl-b-D-galactoside as developing
agent, forming a fluorescent product (4-methyl-umbellif-
erone) fluorescence enzyme immunoassay (FEIA) [20].
The EliA TPOAbs test was a sandwich FEIA method that
used human recombinant TPO antigen. As stated by the
manufacturer, the intra-assay imprecision was 4.1–4.7 %;
the between-assay imprecision was 2.5–4.8 %; the LoD
and the LoQ were not declared.
The Liaison XL was a fully automated CLIA analyzer,
which adopted a flash technology with paramagnetic
microparticles as solid phase [15, 21]. The anti-TPO
Liaison XL 2-step assay was a sandwich CLIA that used
directly coated magnetic microparticles with recombinant
TPO as solid phase and a conjugate based on an isoluminol
derivate. As declared by the manufacturer, the intra-assay
imprecision was 3.6–6.2 %; the between-assay imprecision
was 4.7–6.9 %, the LoD was 0.6 IU/mL and the LoQ was
1.0 IU/mL.
Statistical analysis
All methods were standardized with the reference prepa-
ration MRC 66/387 and used international units (IU),
except for KRY whose results were initially expressed in
arbitrary units and subsequently corrected in IU
Table 1 The main features of the five automated immunoassay methods, as declared by the manufacturers








IMM CLIA Luminescence: adamantyl dioxetane
phosphate
Native TPO 4.9–6.3; nr 6.1–8.1 5.0 nr
MAG CLIA Luminescence: N-(aminobutyl)-N-(ethyl)-
isoluminol
Native TPO 6.8–7.3; 7.4–7.6 nr 0.38 nr
KRY FIA Fluorescence: europium cryptate/XL 665 Native TPO 2.1–7.6; 5.8–16.0 nr 1.8 9.0




4.1–4.7; 2.5–4.8 nr nr nr
LIA CLIA Luminescence: isoluminol derivative Recombinant
TPO
3.6–6.2; 4.7–6.9 nr 0.6 1.0
CLIA chemiluminescence immunoassay, FEIA fluorescence enzyme immunoassay, FIA fluoroimmunoassay, IMM Immulite 2000 XPi, KRY
Kryptor Compact Plus, LIA Liaison XL, LoD limit of detection, LoQ limit of quantitation, MAG Maglumi 2000 Plus, nr not reported, PHA
Phadia 250, TPO thyroid peroxidase
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(conversion factor = 0.175). To compare the data obtained
by the five systems, the results were expressed as a median
and the URL was established at the 99.0th %. The non-
parametric Mann–Whitney U test was used to compare
TPOAbs levels in males and females within the same
method. A two-sided value of p\ 0.05 was considered
statistically significant. The difference between the manu-
facturer’s URL and the experimental URL was expressed
as the ratio between them in percentage (D). The correla-
tion studies were performed on all samples across all the
five methods.
GraphPad Prism, version 4.0 (GraphPad Prism Software,
San Diego, CA, USA) and MedCalc, version 13.3.1
(MedCalc Software, Ostend, Belgium) were used for sta-
tistical analysis.
Results
Value distributions were not Gaussian with a positive skew
in both males and females for all the five methods.
A statistically significant difference (p\ 0.05) between
medians in male and female groups was observed for PHA
(2.6 and 3.1 IU/mL, respectively) but not for the other four
methods.
The scatter plots of TPOAbs values revealed a wide
dispersion with very different coefficient of variation (CV)
between methods, varying from 48.6 % for KRY in
females to 126.3 % for MAG in females (Fig. 1).
URLs differed in males and females according to the
method (Table 2): 28.7 and 29.0 IU/mL for IMM, 24.6 and
25.4 IU/mL for MAG, 6.4 and 6.9 IU/mL for KRY, 8.3
and 10.0 IU/mL for PHA, and 14.2 and 17.9 IU/mL for
LIA, respectively. Such URLs were lower than those stated
by the manufacturers except for LIA in females. The D
between URLs ranged from a minimum of 11.3 % (LIA in
males) to a maximum of 66.8 % (PHA in males).
Correlation analysis showed that all the five methods did
not compare well with each other (Table 3), suggesting
discrepancies between them.
Discussion
To our knowledge, this is the first study on the definition
and comparison of TPOAbs URLs between five different
commercially available automated methods.
The study was designed to accurately define and har-
monize TPOAbs URLs in order to avoid misclassification
of patients in the process of AITD diagnosis. Thus,
according to the NACB recommendations, we evaluated
TPOAbs concentrations and URLs in a reference male
group comparing them with a female one.
The first relevant result of this study was the demon-
stration of a significant difference between the TPOAbs
URLs obtained with the five different automated IMA
methods (both in males and females) and the results
expected according to the corresponding package insert.
Fig. 1 Values of thyroid peroxidase autoantibodies, in males and females, measured by the five automated methods. a Immulite 2000 XPi,
b Maglumi 2000 Plus, c Kryptor Compact Plus, d Phadia 250, e Liaison XL. M males, F females
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With the exception of the LIA method in females, URLs
values obtained in the present study were lower than those
predicted in the insert, with D varying from 11.3 % (LIA in
males) to 66.8 % (PHA in males) (Table 2). This finding
was in contrast to the conclusion of a recent study which
showed that the established URLs were very similar to
those recommended by seven different manufacturers [14].
The difference between that study and the present one
resides in the population sample: in the study by Springer
et al. TPOAbs were measured in women in the first tri-
mester of pregnancy; in the present study, TPOAbs were
determined in 120 healthy males and in 120 healthy
females. The discrepancies between the experimental and
the manufacturer’s URLs, as found in the present study,
could be linked to any of several factors. First of all, there
are racial differences in autoantibody concentrations mea-
sured in different populations over the world: in most
cases, studies, that were sponsored by the test’s manufac-
turer and were conducted in the geographical area of the
production line, may be not reproducible in other geo-
graphical settings. An additional aspect was the lack of
strict criteria in the selection of subjects for the reference
group. In fact, the possibility of enrolling apparently
healthy individuals with subclinical AITD and high levels
of TPOAbs, whose prevalence is estimated around
3.3–25.8 % in the general population, raises the 99th% of
the reference value distribution [12, 13, 15, 22, 23] and
produces an increase in the proportion of subjects classified
as negative for TPOAbs. On the other hand, the demon-
stration of a significant difference between the TPOAbs
URLs obtained with the five different automated IMA
methods both in males and females, confirms the data of a
previous study on the same topic, using indirect methods
[15].
The second relevant consideration emerging from this
study was the dependence of the URLs on the method used.
A decade ago, when third-generation methods were
Table 2 The main statistical
parameters of thyroid
peroxidase autoantibodies, in
males and females, measured by
the five automated
immunoassay methods
Sex No. Mean (CI 95 %) SD CV Median p eURL mURL D
IMM
Males 120 8.2 (7.1–9.3) 6.0 73.6 6.4 0.8 28.7 35.0 18.0
Females 120 8.9 (7.6–10.1) 7.0 79.6 6.7 29.0 17.1
MAG
Males 120 5.5 (4.3–6.6) 6.5 119.8 2.7 0.8 24.6 30.0 18.0
Females 120 4.9 (3.8–6.1) 6.2 126.3 2.2 25.4 15.3
KRY
Males 120 2.7 (2.5–2.9) 1.4 50.6 2.6 0.6 6.4 10.5 39.0
Females 120 2.6 (2.3–2.8) 1.2 48.6 2.4 6.9 34.3
PHA
Males 120 2.8 (2.6–3.1) 1.4 50.9 2.6 \0.05 8.3 25.0 66.8
Females 120 3.7 (3.1–3.8) 1.8 51.8 3.1 10.0 60.0
LIA
Males 120 3.2 (2.6–3.9) 3.4 106.0 1.9 0.8 14.2 16.0 11.3
Females 120 3.2 (2.6–3.9) 3.9 111.3 1.7 17.9 11.9
CV and D are expressed in percentage; Mean, Median, SD, eURL and mURL are expressed in IU/mL.
eURL = 99.0th %; D = jmURL - eURLj/mURL 9 100
CI confidence intervals, CV coefficient of variation, eURL experimental upper reference limit, IMM
Immulite 2000 XPi, KRY Kryptor Compact Plus, LIA Liaison XL, MAG Maglumi 2000 Plus, mURL
manufacturer’s upper reference limit, PHA Phadia 250, SD standard deviation
Table 3 Method comparison
Methods n r (95 % CI)
IMM
MAG 240 0.0011 (-0.1269 to 0.1291)
KRY 240 -0.0235 (-0.1513 to 0.1050)
PHA 240 0.0008 (-0.1266 to 0.1282)
LIA 240 0.0707 (-0.0576 to 0.1966)
KRY
MAG 240 -0.0845 (-0.2108 to 0.0445)
LIA 240 -0.0988 (-0.2247 to 0.0304)
PHA 240 -0.0078 (-0.1362 to 0.1208)
LIA
MAG 240 0.2628 (0.1390 to 0.3786)
PHA 240 0.3679 (0.2521 to 0.4734)
MAG
PHA 240 0.3226 (0.2028 to 0.4330)
CI confidence intervals, IMM Immulite 2000 XPi, KRY Kryptor
Compact Plus, LIA Liaison XL, MAG Maglumi 2000 Plus, PHA
Phadia 250, r correlation coefficient
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introduced the differences between the URL values were
on the order of 4–5 times (from 20.0 to 100.0 IU/mL) [8,
9]. In this study, the differences of the experimental URLs
were similar, but at concentration levels that are four times
lower than those reported in the past, ranging from 6.4 to
28.7 IU/mL in males and from 6.9 to 29.0 IU/mL in
females (Table 2).
The discrepancy of URLs between methods was asso-
ciated with the dispersion of the results obtained by each
method in both the male and female reference groups.
Indeed, the dispersion expressed as CV % showed widely
divergent and fluctuating values, from 48.6 % for KRY to
126.3 % for MAG (Table 2; Fig. 1). There are no clear
explanations for these discrepancies. In fact, over the years,
there has been an improvement in the harmonization
among methods, due to automation of the analytical pro-
cedures and the use of the same reference preparation
(MRC 66/387) [10]. Moreover, it does not seem that the
intra-method analytical imprecision contributes to these
differences, since the precision performances declared by
the individual manufacturer are essentially overlapping
(Table 1). In our opinion, these differences could lie in the
different coating preparations of the TPO antigen (purified
native or recombinant) on solid phase, which affect the
proper exposure of the immunodominant epitopes recog-
nized by the polyclonal antibodies present in serum of
AITD patients (epitopic fingerprint), with the consequent
lack of recognition of some of them [24–26].
Another important result to be noted was the difference
between genders: medians were not statistically significant
different between males and females for IMM, KRY,
MAG, and LIA, while they were different for PHA.
Based on these results, we suggest to overcome the
proposal of NACB guidelines [11], which recommend to
involve a single group of young male subjects in favor of
using two distinct groups, male and female ones. This new
proposal removes the apparent incongruity of using a male
reference group for a disease (such as AITD) affecting
mainly females.
Moreover, in spite of the harmonization among meth-
ods, the wide dispersion of quantitative results, still
observed in this study, suggests the need for further studies
to better understand the cause of these discrepancies,
focusing on TPO antigen preparation as the possible source
of variability among different assays.
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